We describe the development of a highly specific, stable D‐amino peptide RI‐AG03, for inhibition of Tau aggregation that has displayed properties highly desirable in a disease‐modifying therapeutic for Tauopathies. The gene discussed is MAPT; the disease is tauopathy.